From Grey Market to $80 Billion TAM? Why Wall Street Is Suddenly Paying Attention to Peptides
An FT Lex column put potential US peptide sales near $80bn a year. Analysts quoted by Reuters put the market regulatory change would unlock at $2.2 to $3.3bn. Both are right, because they measure different things. The arithmetic behind each.
The $80 billion figure published by the Financial Times Lex column on 9 September 2026 is an extrapolation, not a market measurement: it takes a Citigroup survey in which about 28% of respondents said they had used one of twelve popular peptides and would spend $90 a month, and projects that onto the US adult population. At $1,080 a year per user, the figure implies roughly 74 million paying adults. Analysts quoted by Reuters in July 2026 put the market that an FDA compounding decision would unlock at $2.2 to $3.3 billion, and the approved incretin market generated tens of billions in reported 2025 revenue.
The Financial Times Lex column put potential United States sales of next-generation peptides at roughly $80 billion a year in a piece published on 9 September 2026.1 The number is not a measurement of a market. It is an extrapolation, and Lex is transparent about how it was built: a Citigroup survey in which about 28% of respondents said they had used one of twelve popular peptides and would spend an average of $90 a month, projected onto the adult population. Analysts quoted by Reuters in July put the market that regulatory change would actually unlock at $2.2 to $3.3 billion.2 Both numbers can be right, because they answer different questions. This article separates them. Condor Research supplies reference materials for laboratory research use only; nothing here is investment advice or a recommendation to use any compound.
Where does the $80 billion come from?
From arithmetic that anyone can reproduce. At $90 a month, a user spends $1,080 a year. Eighty billion dollars divided by $1,080 is roughly 74 million people. That is the implied paying population inside the headline: about 74 million American adults buying peptides every month, which is approximately what you get when you take 28% of the United States adult population.1
74m paying adults are implied by the $80 billion figure, at the $90 a month the survey respondents said they would spend.
Stating it that way is not a criticism of the calculation, which is arithmetically correct and clearly labelled by Lex as an implication rather than a forecast. It is a way of making the assumption visible. The question is no longer whether $80 billion is a big number. It is whether 74 million adults is a plausible number of monthly buyers for a category of products that currently cannot be lawfully marketed for human use in the United States.
What does the extrapolation assume?
Three things, each of which moves the answer a lot. First, that survey respondents represent the general adult population. People who answer a survey about peptides are not a random sample of adults, and a usage rate of 28% among them is not a usage rate of 28% among everyone. Second, that stated willingness to pay equals revealed willingness to pay. Survey respondents consistently overstate what they would spend on a hypothetical product. Third, that the regulatory environment permits the category to be sold openly, which today it does not. Lex itself notes that roughly half of non-users cite safety and the absence of scientific evidence as their reason for staying out.1
A total addressable market is a description of a ceiling under assumptions. A market size is a description of money that changed hands.
What is the market actually worth today?
Reuters reported in July 2026 that Needham put the relevant market at up to $3.3 billion, and that Michael Cherny of Leerink estimated $2.2 billion.2 Those figures describe something specific: the business that would open up if the FDA allowed compounding pharmacies to prepare the peptides reviewed by its advisory committee in July 2026. That is a serviceable market conditional on a regulatory decision, not the grey market as it stands and not the ceiling Lex calculates. Needham has separately been reported as putting a broader addressable figure, including grey-market and health-optimisation use, near $30 billion.3
| Figure | What it measures | Source and basis |
|---|---|---|
| About $80bn a year | Ceiling: what US adults might spend if survey behaviour generalised to everyone | Lex extrapolation from a Citigroup survey1 |
| About $30bn | Broader addressable market including grey-market and optimisation use | Analyst estimate reported in press3 |
| $2.2bn to $3.3bn | Serviceable market conditional on the FDA permitting compounding of the reviewed peptides | Needham and Leerink, reported by Reuters2 |
| $36.5bn | Actual 2025 sales of two approved incretin medicines | Eli Lilly reported results for Mounjaro and Zepbound4 |
Four figures that are routinely quoted as if they described the same thing. Only the last is revenue that has been earned and reported; the first three are estimates of different hypothetical perimeters under different conditions.
What does the approved market earn, for scale?
This is the useful benchmark, because it is measured rather than modelled. Eli Lilly reported combined 2025 sales of $36.5 billion for Mounjaro and Zepbound.4 Novo Nordisk reported 2025 sales of DKK 127.1 billion for Ozempic and DKK 79.1 billion for Wegovy.5 In other words, the approved incretin market, built on large outcome trials, insurance reimbursement and two decades of manufacturing investment, is of the same order as the ceiling being projected for an unapproved category. That comparison is the strongest argument for treating the $80 billion figure as a ceiling rather than a forecast.
Why are telehealth companies the ones moving?
Because the business model is already built. Hims and Hers, Ro and LifeMD have prescriber networks, subscription billing and acquisition machinery, which means the marginal cost of adding a category is low. Hims and Hers publicly welcomed the FDA’s move toward regulatory clarity on peptide therapy in April 2026 and said it was exploring how to expand access.6 Its chief executive told investors after the July advisory committee vote that the company could move quickly if the FDA reclassified the peptides in question, and reporting in August indicated plans to offer compounds already permitted, such as sermorelin, glutathione and NAD+, before the end of the year.7 We covered what that entry signals in our piece on peptides going mainstream.
Lex makes a further observation worth keeping: if this category becomes a consumer-goods business, it will be marketed like one, and the marketing spend of consumer brands is a large fraction of revenue.1 A category sold that way competes on brand and distribution, not on evidence, which has implications for who wins and for what buyers end up believing.
What has to be true for the large number to materialise?
At minimum: the FDA has to move the peptides in question to the category that permits compounding, which has not happened and which follows a formal process after an advisory vote that was itself against the recommendation of the agency’s own reviewers. Manufacturing has to exist at pharmaceutical quality and at volume, which is the subject of the current consolidation in peptide capacity. Products have to retain subscribers past the first few months, and adherence in this class is not a solved problem even for approved medicines. And the evidence base has to improve enough to satisfy the half of surveyed non-users who cite its absence. None of those is impossible. All of them are years of work, and each one multiplies through to the final number.
What does this mean for a research-materials supplier?
It is worth being direct about this, since the temptation to claim the large number is obvious. The $80 billion figure describes potential consumer spending on peptides used by people. That is not the category Condor operates in, and the distance between the two is a legal distinction rather than a marketing one, as the FDA’s August 2026 warning letters demonstrated to five companies that blurred it. A research-materials business sells to laboratories, and the addressable market for that is measured in laboratory budgets, not in monthly consumer subscriptions. Anyone quoting the consumer ceiling in support of a research-supply business is describing a market they are not permitted to serve.
What is established, and what is not
Established: the $80 billion figure was published by Lex on 9 September 2026 as an extrapolation from a Citigroup survey; analysts quoted by Reuters in July 2026 put the compounding-conditional market at $2.2 to $3.3 billion; and approved incretin medicines generated tens of billions in reported 2025 revenue.
Not established: the current size of the grey market, for which no audited figure exists because the transactions are not systematically reported. Not established: whether the FDA will reclassify the peptides that the $2.2 to $3.3 billion estimate depends on. Unresolved: whether survey-stated willingness to pay survives contact with a real price and a real subscription. What would change the assessment: an FDA decision, and the first full year of reported revenue from a large telehealth entrant, which would convert one of these estimates into a measurement.
How this was checked. The Lex column of 9 September 2026 was identified with its author and headline, and the survey basis of the $80 billion figure is reported here rather than the figure alone. The implied user count was calculated from the column’s own stated monthly spend. Analyst estimates are attributed to the bank that made them and to the Reuters report that carried them, not presented as Reuters figures. Company revenue is taken from reported annual results, and Novo Nordisk figures are left in Danish kroner because that is the currency in which they are reported. Version 1.0, first published 13 September 2026.
Condor Research supplies characterised reference materials for laboratory research use only: not for human or veterinary use, not for diagnostic or therapeutic application, and not for any food or cosmetic purpose. This article is market and industry commentary. It is not investment advice, not a recommendation regarding any security, and not a suggestion that any compound discussed is appropriate for human use.
Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- The FT Lex column of 9 September 2026 derived roughly $80 billion a year in potential US peptide sales from a Citigroup survey, not from observed revenue.
- The survey basis was about 28% of respondents reporting use of one of twelve popular peptides and stating willingness to spend an average of $90 a month.
- At $90 a month, $80 billion implies about 74 million paying American adults, which is the arithmetic consequence of the extrapolation.
- The extrapolation assumes survey respondents represent the general population, that stated willingness to pay equals actual spending, and that the category can be sold openly.
- Roughly half of surveyed non-users cited safety and the absence of scientific evidence as their reason for not using these products.
- Reuters reported in July 2026 that Needham put the relevant market at up to $3.3 billion and Leerink's Michael Cherny at $2.2 billion, conditional on an FDA compounding decision.
- A broader addressable figure including grey-market and optimisation use has been reported near $30 billion.
- Eli Lilly reported combined 2025 sales of $36.5 billion for Mounjaro and Zepbound; Novo Nordisk reported DKK 127.1 billion for Ozempic and DKK 79.1 billion for Wegovy.
- Telehealth companies are moving first because prescriber networks, subscription billing and acquisition machinery already exist, making the marginal cost of a new category low.
- The consumer ceiling describes spending by people using peptides, which is not the market a research-materials supplier is permitted to serve.
Is the peptide market really worth $80 billion?
No. That figure is a ceiling derived by extrapolation, not a measurement of money that has changed hands. It comes from projecting a survey finding, 28% of respondents reporting use and willingness to spend $90 a month, onto the whole US adult population. At $1,080 a year that implies about 74 million paying adults. It describes what the category could theoretically be worth under strong assumptions.
What is the market worth today?
There is no audited figure, because most of these transactions are not systematically reported. The nearest analyst estimates, reported by Reuters in July 2026, are $2.2 billion from Leerink and up to $3.3 billion from Needham, and both describe a market conditional on the FDA permitting compounding pharmacies to prepare the peptides its advisory committee reviewed, rather than the market as it exists.
What is the difference between TAM, serviceable market and market size?
Total addressable market is the theoretical ceiling if everyone who could buy did. Serviceable market is the portion a company could realistically reach given regulation, distribution and product. Market size is revenue actually earned. The $80 billion figure is the first, the $2.2 to $3.3 billion range is the second under a specific regulatory condition, and the reported sales of approved incretin medicines are the third.
Why are telehealth companies entering this category?
Because their fixed costs are already paid. Prescriber networks, subscription billing and customer acquisition infrastructure exist, so adding a product line is cheap at the margin. Hims and Hers welcomed the FDA's move toward regulatory clarity in April 2026, its chief executive told investors it could act quickly on reclassification, and reporting in August 2026 indicated plans to offer already-permitted compounds before year end.
Does this market forecast apply to research-use-only suppliers?
No, and the distinction is legal rather than commercial. The consumer ceiling describes spending by people taking peptides. A research-materials business supplies laboratories, and its addressable market is laboratory purchasing. The FDA warning letters of August 2026 turned on exactly this line, and any research supplier quoting the consumer number is describing a market it is not permitted to serve.